Hikal Ltd
Anish Swadi, is the Senior President – Animal Health & Business Transformation. He has 24 years of industry experience. He is leading the "Business Transformation" initiative at the company. He is also responsible for Investor Relations and IT operations. He serves on the board of Rx-360, an international pharmaceutical supply chain consortium. Previously, he worked as an International Financial Portfolio Manager with Merrill Lynch in the U.S. Mr. Swadi holds a bachelor’s degree in International Business and Finance from Ithaca College, New York, USA
This person is not in any offices
Hikal Ltd
1 followers
Hikal Limited is engaged in the manufacturing of various chemical intermediates, specialty chemicals, active pharmaceutical ingredients (APIs) and contract research activities. The Company offers pharmaceuticals and agrochemicals. Its segments include Crop Protection and Pharmaceuticals. It offers agrochemicals, including active ingredients, such as Ammonium dithiocarbamate, Amitrole Tech, Diuron Tech, Ethion Tech, Imazalil Tech, Isoproturon Tech, Meta chloro Aniline (MCA), Quinalphos Tech and Temephos Tech, and intermediates and specialty chemicals, such as Phenyl-2-(phenylthio)-phenyl carbamate, 4-(Benzyloxy) Aniline Hydrochloride, N-Benzylpiperidine-4-carboxaldehyde, 3-Chloroaniline and 4 Aminobenzylamine. Its APIs include Gabapentin, Pregabalin, Levetiracetam, Quetiapine Fumarate, Memantine Hydrochloride, Venlafaxine Hydrochloride and Donepezil Hydrochloride. The Company operates in geographical areas, including India, Europe, the United States, Canada and South East Asia.